December 30, 2015
Anavex reports net loss for fiscal year 2015 $12.1M
Anavex had cash and cash equivalents of $15.3 million as of September 30, 2015, compared with $7.3 million as at…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Christopher U. Missling
November 18, 2015
Anavex prepares for regulatory filings based on FDA guidance
Anavex is moving forward with the development program for ANAVEX 2-73 for the treatment of Alzheimer’s disease in a…
September 28, 2015
Anavex: Phase 2a clinical trial of ANAVEX 2-73 completed
Anavex Life Sciences Corp, a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS)…
September 21, 2015
Harald Hampel to Become Anavexs Scientific Advisory Board Member
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS)…